About 30 results found for searched term "AK-7" (0.032 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1750 | TAK-733 | MEK |
| TAK-733 is a potent and selective MEK allosteric site inhibitor with IC50 of 3.2nM for the treatment of cancer. | ||
| M2054 | Fasiglifam (TAK-875) Hemihydrate | GPR/FFAR |
| Fasiglifam Hemihydrate; TAK875 hydrate | ||
| Fasiglifam (TAK-875) Hemihydrate is a novel, orally available, selective GPR40 agonist. | ||
| M3048 | TAK-715 | p38 MAPK |
| TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. | ||
| M11432 | Razuprotafib | Phosphatase |
| AKB-9778 | ||
| Razuprotafib (AKB-9778) is an effective selective inhibitor of VE-PTP (HPTPß) catalytic activity (IC50=17 pM). | ||
| M3750 | TAK-700 | Androgen Receptor |
| Orteronel | ||
| TAK-700 (Orteronel) is an investigational, oral, nonsteroidal, selective, reversible inhibitor of 17,20-lyase, a key enzyme in the production of androgenic hormones. | ||
| M5798 | Mosapride | 5-HT Receptor |
| TAK-370; AS-4370 | ||
| Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist. | ||
| M5919 | Ramelteon (TAK-375) | Melatonin Receptor |
| TAK-375 | ||
| Ramelteon (TAK-375) is a novel melatonin receptor agonist for human MT1 and MT2 receptors and chick forebrain melatonin receptors with Ki of 14 pM, 112 pM and 23.1 pM, respectively. | ||
| M6175 | Serabelisib | PI3K |
| INK-1117,MLN-1117,TAK-117 | ||
| Serabelisib (INK-1117,MLN-1117,TAK-117) is a potent and selective oral PI3Kα isoform inhibitor (IC50 of 21 nmol/L against PI3Kα) that has demonstrated > 100-fold selectivity relative to other class I PI3K family members (PI3Kβ/γ/δ) and mTOR, and a high degree of selectivity against many other kinase. | ||
| M6258 | IRAK4-IN-7 | IRAK |
| CA-4948; CA4948; Emavusertib | ||
| IRAK4-IN-7 is a selective, potent and orally active inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) that regulates IRAK4 function in the TLR and IL-1R signaling cascades. It has good pharmacokinetic characteristics and antitumor activity in vitro and in vivo. | ||
| M6906 | Levcromakalim | Potassium Channel |
| (-)-Cromakalim; BRL 38227 | ||
| Levcromakalim is a k ir6 (K ATP) channel opener; active enantiomer of cromakalim. | ||
| M8244 | AK-7 | Sirtuin |
| AK7 | ||
| AK-7 is a brain penetrant selective SIRT2 inhibitor, with an IC50 of 15.5 μM. | ||
| M9135 | TAK-779 | CCR |
| Takeda 779; TAK779 Chloride | ||
| TAK-779 is a potent and selective nonpeptide antagonist of CCR5, with a Ki of 1.1 nM for CCR5. | ||
| M9535 | Mobocertinib | EGFR/HER2 |
| TAK-788; AP32788 | ||
| Mobocertinib (TAK-788) is an investigational TKI with potent, selective preclinical activity against activating EGFR and HER2 mutations, including exon 20 insertions. | ||
| M10476 | GDC-0575 (ARRY-575) | Checkpoint |
| RG7741; ARRY575; AK-687476 | ||
| GDC-0575 (ARRY-575, RG7741) is a potent and selective oral inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2 nM. | ||
| M13962 | Fasiglifam | FAS |
| TAK-875 | ||
| Fasiglifam (TAK-875) is a potent, selective and orally bioavailable GPR40 agonist with EC50 of 72 nM. | ||
| M14126 | Avatrombopag hydrochloride | Thrombopoietin/Thrombin |
| AKR-501 hydrochloride; E5501 hydrochloride; YM477 hydrochloride | ||
| Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. | ||
| M14138 | Mobocertinib succinate | EGFR/HER2 |
| TAK-788 succinate; AP32788 succinate | ||
| Mobocertinib succinate (TAK-788 succinate) is a potent and orally active inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, with selectivity over WT EGFR. Antitumor activity. | ||
| M20001 | Testolactone | Others |
| sq9538;teolit;teslac;teslak;nsc-12173 | ||
| Testolactone was originally synthesized as a possible anabolic steroid. The key structural difference from anabolic steroids is the D-cyclolactone rather than the typical cyclopentyl ring. | ||
| M20390 | TAK-700 (Orteronel) | Cytochrome P450 (e.g. CYP17) |
| TAK-700 (Orteronel) is a potent and highly selective human 17,20-lyase inhibitor with IC50 of 38 nM, exhibits >1000-fold selectivity over other CYPs (e.g. 11-hydroxylase and CYP3A4). Phase 3. | ||
| M20971 | Avatrombopag | Thrombopoietin/Thrombin |
| AKR-501; E5501; YM477 | ||
| Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system. | ||
| M21179 | TAK-071 | Others |
| TAK-071 is a novel, potent and selective modulator of muscarinic acetylcholine receptor 1 (M1R) orthostructure. TAK-071 activates M1R with an EC50 of 520 nM. | ||
| M24814 | Valziflocept | Others |
| BAX1810; TAK-752 | ||
| Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE). | ||
| M25011 | Mezagitamab | Others |
| TAK-079 | ||
| Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP). | ||
| M25058 | Modakafusp alfa | Others |
| TAK-573 | ||
| Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules. Modakafusp alfa can be used in the research of multiple myeloma. | ||
| M25158 | Ligufalimab | IL Receptor/Related |
| AK 117 | ||
| Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity. | ||
| M25460 | Zasocitinib | JAK |
| NDI-034858; TAK-279 | ||
| Zasocitinib (NDI-034858) is a highly selective, orally active TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM. | ||
| M28996 | Lapaquistat acetate | Others |
| TAK-475 | ||
| Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway. Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research. | ||
| M29635 | PROTAC IRAK4 degrader-7 | PROTAC |
| KT-474; SAR444656 | ||
| PROTAC IRAK4 degrader-7 (Compound I-417) is a potentially first-in-class, orally active PROTAC IRAK4 degrader with antitumor activity for studies related to hidradenitis suppurativa (HS) and atopic dermatitis (AD). | ||
| M29703 | Dazostinag | STING |
| TAK-676 free base | ||
| Dazostinag (TAK-676 free base) is an agonist of stimulator of interferon genes (STING) protein with antineoplastic activity. Dazostinag can serve as a playload to synthesis antibody-drug conjugates (ADCs). | ||
| M29704 | Dazostinag disodium | STING |
| TAK-676 | ||
| Dazostinag disodium (TAK-676) is an agonist of STING, triggering the activation of STING signaling pathway and type I interferons. Dazostinag disodium is also a modulator of immune system, resulting complete regressions and durable memory T-cell immunity. Dazostinag disodium promotes durable IFN-dependent antitumor immunity. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
